Biosig Technologies (NASDAQ:STEX) Price Target Cut to $9.00 by Analysts at Needham & Company LLC

Biosig Technologies (NASDAQ:STEX) had its target price decreased by Needham & Company LLC from $12.00 to $9.00 in a research note published on Thursday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

A number of other equities analysts have also commented on STEX. Weiss Ratings initiated coverage on shares of Biosig Technologies in a research report on Friday, January 23rd. They issued a “sell (d-)” rating on the stock. Wall Street Zen lowered shares of Biosig Technologies from a “hold” rating to a “strong sell” rating in a research report on Sunday, April 5th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $9.00.

Biosig Technologies Stock Performance

Shares of STEX opened at $1.05 on Thursday. The company has a market capitalization of $187.45 million, a price-to-earnings ratio of -0.11 and a beta of 1.90. The company’s 50 day simple moving average is $2.05. Biosig Technologies has a twelve month low of $0.49 and a twelve month high of $14.11.

Biosig Technologies (NASDAQ:STEX) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($8.23) EPS for the quarter.

Insider Transactions at Biosig Technologies

In related news, CIO Mitchell Young Williams acquired 51,511 shares of the stock in a transaction dated Friday, January 23rd. The shares were acquired at an average price of $3.03 per share, for a total transaction of $156,078.33. Following the completion of the purchase, the executive owned 1,051,511 shares in the company, valued at approximately $3,186,078.33. The trade was a 5.15% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Frank Giustra acquired 100,000 shares of the stock in a transaction dated Wednesday, February 4th. The stock was bought at an average price of $3.17 per share, for a total transaction of $317,000.00. Following the purchase, the insider owned 1,278,205 shares of the company’s stock, valued at $4,051,909.85. The trade was a 8.49% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have purchased 1,267,011 shares of company stock worth $3,825,628. Insiders own 52.73% of the company’s stock.

About Biosig Technologies

Biosig Technologies (NASDAQ:STEX) is a medical technology company focused on developing advanced signal acquisition and processing solutions for cardiac electrophysiology. The company’s work centers on improving the clarity and interpretability of intracardiac signals captured during electrophysiology procedures, with the goal of helping clinicians identify arrhythmogenic substrates and make more informed procedural decisions.

Its primary offering is a signal-processing platform that combines proprietary hardware and software to amplify, filter and display intracardiac electrical activity with reduced noise and distortion.